These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Bacteriophage therapy in children: facts and prospects. Fortuna W; Miedzybrodzki R; Weber-Dabrowska B; Górski A Med Sci Monit; 2008 Aug; 14(8):RA126-32. PubMed ID: 18668009 [TBL] [Abstract][Full Text] [Related]
4. [The bacteriophages and their gene products as antimicrobial agents]. García E; López R Rev Esp Quimioter; 2002 Dec; 15(4):306-12. PubMed ID: 12587035 [TBL] [Abstract][Full Text] [Related]
5. Review: phage therapy: a modern tool to control bacterial infections. Qadir MI Pak J Pharm Sci; 2015 Jan; 28(1):265-70. PubMed ID: 25553704 [TBL] [Abstract][Full Text] [Related]
6. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Kutateladze M; Adamia R Trends Biotechnol; 2010 Dec; 28(12):591-5. PubMed ID: 20810181 [TBL] [Abstract][Full Text] [Related]
7. Engineering microbes for targeted strikes against human pathogens. Hwang IY; Lee HL; Huang JG; Lim YY; Yew WS; Lee YS; Chang MW Cell Mol Life Sci; 2018 Aug; 75(15):2719-2733. PubMed ID: 29736607 [TBL] [Abstract][Full Text] [Related]
8. Treatment of post-burns bacterial infections by bacteriophages, specifically ubiquitous Pseudomonas spp. notoriously resistant to antibiotics. Ahmad SI Med Hypotheses; 2002 Apr; 58(4):327-31. PubMed ID: 12027527 [TBL] [Abstract][Full Text] [Related]
12. Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future. Łobocka M; Dąbrowska K; Górski A BioDrugs; 2021 May; 35(3):255-280. PubMed ID: 33881767 [TBL] [Abstract][Full Text] [Related]
13. Construction of a genetically modified T7Select phage system to express the antimicrobial peptide 1018. Lemon DJ; Kay MK; Titus JK; Ford AA; Chen W; Hamlin NJ; Hwang YY J Microbiol; 2019 Jun; 57(6):532-538. PubMed ID: 31054139 [TBL] [Abstract][Full Text] [Related]
14. Biofilm control with natural and genetically-modified phages. Motlagh AM; Bhattacharjee AS; Goel R World J Microbiol Biotechnol; 2016 Apr; 32(4):67. PubMed ID: 26931607 [TBL] [Abstract][Full Text] [Related]
15. Genetically Engineered Phages: a Review of Advances over the Last Decade. Pires DP; Cleto S; Sillankorva S; Azeredo J; Lu TK Microbiol Mol Biol Rev; 2016 Sep; 80(3):523-43. PubMed ID: 27250768 [TBL] [Abstract][Full Text] [Related]
16. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. Ryan EM; Gorman SP; Donnelly RF; Gilmore BF J Pharm Pharmacol; 2011 Oct; 63(10):1253-64. PubMed ID: 21899540 [TBL] [Abstract][Full Text] [Related]
17. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
18. Phage therapy: past history and future prospects. Carlton RM Arch Immunol Ther Exp (Warsz); 1999; 47(5):267-74. PubMed ID: 10604231 [TBL] [Abstract][Full Text] [Related]
19. Antibodies as delivery vehicles for radioimmunotherapy of infectious diseases. Dadachova E; Casadevall A Expert Opin Drug Deliv; 2005 Nov; 2(6):1075-84. PubMed ID: 16296810 [TBL] [Abstract][Full Text] [Related]
20. Antibacterial application of engineered bacteriophage nanomedicines: antibody-targeted, chloramphenicol prodrug loaded bacteriophages for inhibiting the growth of Staphylococcus aureus bacteria. Vaks L; Benhar I Methods Mol Biol; 2011; 726():187-206. PubMed ID: 21424451 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]